What chemotherapeutic regimen would you prefer in patients with T1N0 triple-negative breast cancer, assuming no contraindications to taxanes and anthracyclines?

In the joint analysis of the ABC (Anthracyclines in early Breast Cancer) presented at ASCO 2016 there was a 30% relative increased risk of invasive recurrence for women with ER/PR-negative, node-negative disease when an anthracycline was omitted (HR 1.31). Further subset analyses by tumor size were ...

Although the relative risk reduction provided by anthracycline-based chemotherapy in triple negative breast cancer may be significant, on an absolute level, for a T1 N0 disease, it may be marginal. Such a marginal benefit is offset by quite significant toxicities. Therefore, in my practice, I genera...